Shanghai Henlius Biotech and Organon (OGN) announced the European Commission has granted marketing authorization for Poherdy 420 mg/14 mL injection for intravenous use. In 2022, Henlius entered into a license and supply agreement with Organon, granting Organon the exclusive commercialization rights to several biosimilars, including Poherdy. The agreement covers exclusive global commercialization rights except for China.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGN: